中国科学院大学
University of Chinese Academy of Sciences
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 19 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 6
- 牵头的研究论文
- 19
- 牵头的试验
- 26
- 占中国试验的比例
- 4.4%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial.
- Concurrent chemotherapy for older patients with locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial.
- Effect of Dendrobium Officinale on Radioactive Oral Mucositis of Nasopharyngeal Carcinoma and Changes of Oral Microecology.
- Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.
- Nasopharyngeal Giant Carcinoma Mimicking Intracranial Lesions: A Case Report and Literature Review.
ClinicalTrials.gov 上的试验6
- Platinum-Free Regimen in Nasopharyngeal Carcinoma
- Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
- Metastatic Nasopharyngeal Carcinoma
- Radiotherapy Combined With Endostatin and Capecitabine for NPC
- SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
- Immune Score Based Radiomics in Nasopharyngeal Carcinoma
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 50 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 6
- 牵头的研究论文
- 50
- 牵头的试验
- 16
- 占中国试验的比例
- 2.8%
- 占全球论文的比例
- 1.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospect
- A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma.
- Development and validation of a novel pre-operative comprehensive prognostic score in esophageal squamous cell carcinoma.
- Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.
- Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy.
ClinicalTrials.gov 上的试验6
- Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
- Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)
- Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
- A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
- Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
- Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 35 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 3
- 牵头的研究论文
- 35
- 牵头的试验
- 9
- 占中国试验的比例
- 0.6%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Comparison of the effective dose of alfentanil for percutaneous thermal ablation in subcapsular versus non-subcapsular hepatocellular carcinoma: a prospective dose-finding study utilizing the up-and-down sequential alloc
- Integrating cell-free DNA methylation of SEPT9 and SFRP2 into a machine learning model for early diagnosis of HCC.
- Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.
- Combined image-guided radiofrequency and iodine-125 seeds implantation in the treatment of recurrent hepatocellular carcinoma after hepatectomy.
- Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma.
ClinicalTrials.gov 上的试验6
- Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
- Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
- GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 106 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 11
- 牵头的研究论文
- 106
- 牵头的试验
- 36
- 占中国试验的比例
- 2.5%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.
- Development and validation of nomogram for predicting early recurrence after radical gastrectomy of gastric cancer.
- Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study.
- AI-based large-scale screening of gastric cancer from noncontrast CT imaging.
- Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.
ClinicalTrials.gov 上的试验6
- A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
- Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
- Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
- Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
- Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
- QL1706 Combined With SOX Used in Theperioperative Treatment
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.04%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验1
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.02%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
再生障碍性贫血
Aplastic anaemia2021–2025年中国大陆共有 412 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis (HLH)2021–2025年中国大陆共有 399 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
范可尼贫血
Fanconi anaemia2021–2025年中国大陆共有 68 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。